7 completed, 6 active not recruiting, 3 recruiting, 2 not yet recruiting. 13 Phase 2, 3 Phase 1, 2 Phase 3, 1 Not applicable.
Follow Papillary Renal Cell Carcinoma: new trials by email Literature Review of Papillary Renal Cell Carcinoma trials Research Report on Papillary Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer Proteomic profiling of urinary EVs, Blood sample collection - Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma | Not yet recruiting | Mayo Clinic | 300 | 2026-07-15 | 2026-02-27 | |
| Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC Observational, None intervention - Papillary Renal Cell Carcinoma | Completed | AstraZeneca | 48 | 2025-03-31 | 2026-09-25 | |
| Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy Pembrolizumab, Placebo - Papillary Renal Cell Carcinoma | Phase 3 | Not yet recruiting | First Affiliated Hospital, Sun Yat-Sen University | 468 | 2023-12-01 | 2023-11-29 |
| Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer JK08, Pembrolizumab, Lenvatinib Pill - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Active not recruiting | Salubris Biotherapeutics Inc | 263 | 2022-10-17 | 2024-10-15 |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer Atezolizumab, Bevacizumab, Biopsy Procedure - Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 65 | 2022-06-10 | 2026-09-29 |
| Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC savolitinib, durvalumab, sunitinib - Papillary Renal Cell Carcinoma | Phase 3 | Active not recruiting | AstraZeneca | 148 | 2021-10-28 | 2026-10-21 |
| Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer Pamiparib, Temozolomide - Clear Cell Papillary Renal Neoplasm, Collecting Duct Carcinoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2021-10-18 | 2023-05-17 | |
| Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC Cabozantinib, Nivolumab, Ipilimumab - Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma | Phase 2 | Active not recruiting | Bradley A. McGregor, MD | 60 | 2020-11-05 | 2026-07-23 |
| Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 98 | 2020-07-29 | 2026-09-28 |
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy 13C-Glucose, 13C-Acetate, 13C-Lactate - Kidney Cancer, Renal Cell Carcinoma | Not applicable | Recruiting | University of Texas Southwestern Medical Center | 600 | 2019-09-30 | 2026-01-28 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-10-22 |
| A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma cabozantinib, nivolumab - Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2018-08-13 | 2026-09-21 |
| Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study Non-Interventional Study - Chromophobe Renal Cell Carcinoma, Clear Cell Papillary Renal Tumor | Completed | Mayo Clinic | 589 | 2018-06-27 | 2026-07-01 | |
| Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma Cabozantinib, Sunitinib Malate - Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2018-05-15 | 2026-07-16 |
| A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma CDX-014 - Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma | Phase 1 | Terminated | Celldex Therapeutics | 16 | 2016-06-01 | 2020-06-04 |
| Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma Axitinib - Papillary Renal Cell Carcinoma | Phase 2 | Completed | Centre Leon Berard | 44 | 2015-10-01 | 2022-09-06 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Pazopanib Hydrochloride - Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma | Phase 2 | Completed | Mayo Clinic | 38 | 2013-05-16 | 2025-03-03 |
| Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery - Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 2 | Completed | Children's Oncology Group | 291 | 2006-06-01 | 2017-07-21 |
| Study of Kidney Tumors in Younger Patients Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor | Completed | Children's Oncology Group | 8000 | 2006-02-27 | 2026-05-18 | |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer Bevacizumab, Sorafenib Tosylate, Pharmacological Study - Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 73 | 2005-05-01 | 2015-01-15 |
Showing 20 of 21. Sign in to see all of them.
Carcinoma, Renal Cell (21) · Carcinoma, Transitional Cell (4) · Kidney Neoplasms (4) · Hereditary leiomyomatosis and renal cell cancer (3) · Neoplasm Metastasis (3) · Oncocytoma, renal (3) · Wilms Tumor (2) · Adenocarcinoma, Clear Cell (1) · Angiolipoma (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Fumaric aciduria (1)
Adenocarcinoma (21) · Female Urogenital Diseases (21) · Female Urogenital Diseases and Pregnancy Complications (21) · Male Urogenital Diseases (21) · Neoplasms by Histologic Type (21) · Neoplasms by Site (21) · Neoplasms, Glandular and Epithelial (21) · Urogenital Diseases (21) · Urologic Diseases (21) · Carcinoma (20) · Kidney Diseases (20) · Neoplasms (20) · Urogenital Neoplasms (20) · Urologic Neoplasms (20) · Kidney Neoplasms (17)
cabozantinib (5) · Magnetic Resonance Spectroscopy (3) · Nivolumab (3) · Specimen Handling (3) · Bevacizumab (2) · Ipilimumab (2) · Sorafenib (2) · Sunitinib (2) · pembrolizumab (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Axitinib (1) · Biopsy (1) · CTLA-4 Antigen (1) · Carboplatin (1) · Congresses as Topic (1)
National Cancer Institute (NCI) (5) · Mayo Clinic (3) · AstraZeneca (2) · Children's Oncology Group (2) · Bradley A. McGregor, MD (1) · Celldex Therapeutics (1) · Centre Leon Berard (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Salubris Biotherapeutics Inc (1) · University of Texas Southwestern Medical Center (1)
United States (16) · Australia (3) · Canada (3) · Puerto Rico (3) · China (2) · France (2) · Israel (2) · New Zealand (2) · Spain (2) · Argentina (1) · Belgium (1) · Brazil (1) · Chile (1) · Czechia (1) · Germany (1)
Andrea B Apolo (1) · Bradley McGregor, MD (1) · Brian Costello, M.D. (1) · Brian Shuch, MD (1) · Daniel George (1) · Darren Feldman, MD (1) · DingWei Ye, Postdoctoral (1) · Elizabeth A Mullen (1) · Fabrice Lucien-Matteoni, MD (1) · Jeffrey Dome, MD (1) · Jeffrey Sosman (1) · John B. Kisiel, MD (1) · Jun-Hang Luo, M.D. (1) · Matthew T Campbell (1) · Ramaprasad Srinivasan (1)
PMID 38396300, PMID 32267967, PMID 32472319, PMID 33604999, PMID 35031545, PMID 35298296, PMID 37933882, PMID 37935564, PMID 41861260, PMID 42507969, PMID 42657661
U10CA098543 (2), U10CA180821 (2), F31CA239330 (1), P30CA068485 (1), P50CA196516 (1), R35CA220449 (1), U01CA099118 (1), U01CA099177 (1), U10CA180886 (1), UG1CA189958 (1)